Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Laura Lazzeri

Showing results (11-20 of 17) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 17 results.
Journal of Clinical Medicine|July 13, 2024
Long-Term Persistence Rate of Secukinumab in Psoriatic Patients: A Six-Year Multicenter, Real-World Experience, Retrospective StudyMarco Galluzzo, Emanuele Trovato, Marina Talamonti, et al.
Italian Journal of Dermatology and Venereology|January 12, 2026
T2-Reg: a regional web registry on Th2-mediated diseasesMartina D'Onghia, Giovanni Rubegni, Flavia Manzo Margiotta, et al.
Clinical and Experimental Dermatology|July 15, 2025
Therapeutic Outcomes Across JAK Inhibitors in Prurigo NodularisGianluca Avallone, Andrea Bombelli, Luca Valtellini, et al.
International Journal of Dermatology|August 21, 2025
Incidence, Risk Factors, and Management of Conjunctivitis in Atopic Dermatitis Patients Treated With Dupilumab or Tralokinumab: Results From a Multicenter, Observational, Retrospective StudyLuca Potestio, Cataldo Patruno, Marika Del Gaudio, et al.
Clinical and Experimental Dermatology|October 30, 2025
Psoriasis and Seronegative Spondyloarthropathy in Atopic Dermatitis Patients Treated with Dupilumab or Tralokinumab: A Multicentre Observational StudyGiuseppe Lauletta, Cataldo Patruno, Luca Potestio, et al.
Clinical and Experimental Dermatology|June 27, 2025
Clinical Course of Atopic Dermatitis after Dupilumab Discontinuation: A Multicenter Real-World StudyFrancesca Barei, Stefano Macchi, Paolo Calzari, et al.
Clinical and Experimental Dermatology|April 15, 2026
Dupilumab for Prurigo Nodularis: Real-World Outcomes Up to 104 Weeks from the DUPItaPN StudyMarina Talamonti, Edoardo Mortato, Alessandra Narcisi, et al.
Pageof 2

Showing results (11-20 of 17) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 17 results.
Journal of Clinical Medicine|July 13, 2024
Long-Term Persistence Rate of Secukinumab in Psoriatic Patients: A Six-Year Multicenter, Real-World Experience, Retrospective StudyMarco Galluzzo, Emanuele Trovato, Marina Talamonti, et al.
Italian Journal of Dermatology and Venereology|January 12, 2026
T2-Reg: a regional web registry on Th2-mediated diseasesMartina D'Onghia, Giovanni Rubegni, Flavia Manzo Margiotta, et al.
Clinical and Experimental Dermatology|July 15, 2025
Therapeutic Outcomes Across JAK Inhibitors in Prurigo NodularisGianluca Avallone, Andrea Bombelli, Luca Valtellini, et al.
International Journal of Dermatology|August 21, 2025
Incidence, Risk Factors, and Management of Conjunctivitis in Atopic Dermatitis Patients Treated With Dupilumab or Tralokinumab: Results From a Multicenter, Observational, Retrospective StudyLuca Potestio, Cataldo Patruno, Marika Del Gaudio, et al.
Clinical and Experimental Dermatology|October 30, 2025
Psoriasis and Seronegative Spondyloarthropathy in Atopic Dermatitis Patients Treated with Dupilumab or Tralokinumab: A Multicentre Observational StudyGiuseppe Lauletta, Cataldo Patruno, Luca Potestio, et al.
Clinical and Experimental Dermatology|June 27, 2025
Clinical Course of Atopic Dermatitis after Dupilumab Discontinuation: A Multicenter Real-World StudyFrancesca Barei, Stefano Macchi, Paolo Calzari, et al.
Clinical and Experimental Dermatology|April 15, 2026
Dupilumab for Prurigo Nodularis: Real-World Outcomes Up to 104 Weeks from the DUPItaPN StudyMarina Talamonti, Edoardo Mortato, Alessandra Narcisi, et al.
Pageof 2